BL-M07D1 + pertuzumab + taxane

A combination therapy composed of **BL-M07D1 (trastuzumab brengitecan)**, **pertuzumab**, and a **taxane** (taxane class, commonly docetaxel or paclitaxel) used for the neoadjuvant or metastatic treatment of **HER2-positive breast cancer** and other HER2-expressing solid tumors. - **BL-M07D1** is an investigational **antibody-drug conjugate (ADC)** that consists of a humanized trastuzumab antibody targeting **HER2**, linked via a cathepsin B cleavable linker to Ed-04 (a camptothecin-derived topoisomerase I inhibitor). Its mechanism combines selective HER2 antagonism and potent DNA topoisomerase I inhibition, impeding tumor cell division and inducing apoptosis. - **Pertuzumab** is a monoclonal antibody that binds to a different epitope on HER2 than trastuzumab, blocking ligand-dependent dimerization and downstream signaling. - **Taxane** agents (such as docetaxel or paclitaxel) are standard chemotherapeutics that stabilize microtubules, leading to mitotic arrest and cell death. This combination is being evaluated in phase II/III trials for efficacy and safety in HER2-positive breast cancer, particularly in neoadjuvant settings, and may have application in other HER2-expressing cancers[2][3][5][7][8][9].

Other names

Trastuzumab brengitecan + pertuzumab + taxane